Get started
Author

Guiling Li

Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial
2023 · Xiangyu Gao, Nong Xu, et al. · The Lancet Oncology · 226
Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China
2024 · Xiaohua Wu, Yang Sun, et al. · The Lancet · 134
Ovarian Masses in Children and Adolescents - An Analysis of 521 Clinical Cases
2013 · Mingxing Zhang, Wei Jiang, et al. · Journal of Pediatric and Adolescent Gynecology · 130
Targeting CD96 overcomes PD-1 blockade resistance by enhancing CD8+ TIL function in cervical cancer
2022 · Yumeng Wang, Congwen Wang, et al. · Journal for ImmunoTherapy of Cancer · 76
PDF
Efficacy and safety of cadonilimab, an anti-PD-1/CTLA4 bi-specific antibody, in previously treated recurrent or metastatic (R/M) cervical cancer: a multicenter, open-label, single-arm, phase II trial (075)
2022 · Xiaohua Wu, Jiafu Ji, et al. · Gynecologic Oncology · 63
Minimal deviation adenocarcinoma of the uterine cervix
2010 · Guiling Li, Wei Jiang, et al. · International Journal of Gynecology & Obstetrics · 60
HPV E6 down-regulation and apoptosis induction of human cervical cancer cells by a novel lipid-soluble extract (PE) from Pinellia pedatisecta Schott in vitro
2010 · Gui-Ling Li, Wei Jiang, et al. · Journal of Ethnopharmacology · 51
PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives
2019 · Yumeng Wang, Guiling Li · Frontiers of Medicine · 49
Enhanced antitumor effects of follicle-stimulating hormone receptor-mediated hexokinase-2 depletion on ovarian cancer mediated by a shift in glucose metabolism
2020 · Meng Zhang, Qiyu Liu, et al. · Journal of Nanobiotechnology · 39
PDF
A study of AK104 (an anti-PD1 and anti-CTLA4 bispecific antibody) combined with standard therapy for the first-line treatment of persistent, recurrent, or metastatic cervical cancer (R/M CC).
2022 · Jing Wang, Hanmei Lou, et al. · Journal of Clinical Oncology · 38
A novel ferroptosis-related gene signature for predicting outcomes in cervical cancer
2021 · Xingling Qi, Yipeng Fu, et al. · Bioengineered · 36
PDF
Anti-LAG-3 antibody LBL-007 plus anti-PD-1 antibody toripalimab in advanced nasopharyngeal carcinoma and other solid tumors: an open-label, multicenter, phase Ib/II trial
2025 · Gang Chen, Dong-Chen Sun, et al. · Journal of Hematology & Oncology · 35
PDF
Clinical analysis of uterine intravenous leiomyomatosis: A retrospective study of 260 cases
2021 · Jing Peng, Fangfang Zhong, et al. · Journal of obstetrics and gynaecology research · 31
A lipid-soluble extract of Pinellia pedatisecta Schott orchestrates intratumoral dendritic cell-driven immune activation through SOCS1 signaling in cervical cancer
2020 · Yumeng Wang, Chong Lu, et al. · Journal of Ethnopharmacology · 24
A lipid-soluble extract of Pinellia pedatisecta Schott enhances antitumor T cell responses by restoring tumor-associated dendritic cell activation and maturation
2019 · Yumeng Wang, Haixia Huang, et al. · Journal of Ethnopharmacology · 24
Pretreatment Neutrophil-to-Lymphocyte Ratio and Lactate Dehydrogenase Predict the Prognosis of Metastatic Cervical Cancer Treated with Combination Immunotherapy
2022 · Mingxia Cheng, Guiling Li, et al. · Journal of Oncology · 18
PDF
Epitomics: IgG-epitome decoding of E6, E7 and L1 proteins from oncogenic human papillomavirus type 58
2016 · Wan-Xiang Xu, Jian Wang, et al. · Scientific Reports · 18
PDF
Efficacy and safety of serplulimab plus nab-paclitaxel in previously treated patients with PD-L1–positive advanced cervical cancer: a phase II, single-arm study
2023 · Jusheng An, Xiumin Li, et al. · Frontiers in Immunology · 16
PDF
Clinical Efficacy and Safety of Immunotherapy Retreatment in Metastatic Cervical Cancer: A Retrospective Study
2023 · Guiling Li, Mingxia Cheng, et al. · OncoTargets and Therapy · 15
PDF
Triglycerides/high-density lipoprotein-cholesterol ratio outperforms traditional lipid indicators in predicting metabolic dysfunction-associated steatotic liver disease among U.S. adults
2025 · Jin Yuan, Xuequan He, et al. · Frontiers in Endocrinology · 14
PDF
Combining cisplatin with Pinellia pedatisecta Schott lipid-soluble extract induces tumor immunogenic cell death in cervical cancer
2024 · Congwen Wang, Mingxing Zhang, et al. · Phytomedicine · 14
PD-L1 regulation by SDH5 via β-catenin/ZEB1 signaling
2019 · Zhan Tuo, Yan Zong, et al. · OncoImmunology · 14
Phase II study of enlonstobart (SG001), a novel PD-1 inhibitor in patients with PD-L1 positive recurrent/metastatic cervical cancer
2024 · Guiling Li, Xiaofan Li, et al. · Gynecologic Oncology · 11
PDF
Sintilimab combined with bevacizumab in relapsed/persistent ovarian clear cell carcinoma (INOVA): an investigator-initiated, multicentre clinical trial—a study protocol of clinical trial
2022 · Ruyuan Li, Xingyu Liu, et al. · BMJ Open · 11
PDF
Use of new-media health information among the elderly and its effect on their health and health management
2024 · Haojie Xie, Dongxu Wu, et al. · BMC Public Health · 10
Works count: 54
Citation count: 1,239
H-index: 17
I10-index: 25
Year
Topic
Type